Researchers are looking for a better way to treat women with nonatypical endometrial hyperplasia (NAEH). Endometrial hyperplasia is a condition where the lining of the uterus (called the endometrium) becomes too thick. Nonatypical means that the condition is not cancerous. It is often caused by hormone imbalances in women. Symptoms can include abnormal vaginal bleeding or irregular periods. If this condition is not treated, then it may lead to cancer. Currently, there are no approved treatments for NAEH and that is why there is still an unmet medical need. The study treatment, Mirena (also known as BAY 865028), is already available as a type of birth control device. It is inserted into the uterus where it gradually releases progesterone. In this study, researchers want to find out if Mirena works for women with NAEH. They believe it can help by keeping hormone levels balanced in the body. The main purpose of this study is to show that uterine lining goes back to completely normal lining after treatment with Mirena and that its use is safe in this population. For this, the researchers will compare the number of participants with benign endometrium after 6 months of treatment with Mirena or oral MPA. The study participants will be randomly assigned into one of two treatment groups. The randomization will be done 2:1 ratio, meaning that for every two participants assigned to Mirena, one will be assigned to oral medroxyprogesterone acetate (MPA). Based on their group, participants will receive Mirena, which is inserted into the uterus at the start of the study, or they will take progestins once daily by mouth for 6 months. Each participant will be in the study for around 10 months with up to 5 visits to the study clinic/site. Participants will visit the study clinic: * once before the treatment starts * 3 times with a gap of 3 months between the visits during the treatment * then 1 more time after the treatment ends During the study, the doctors and their study team will: * check participant's health by performing tests such as blood and urine tests * perform vaginal ultrasound and hysteroscopy. Hysteroscopy is a minor surgical procedure where a thin camera will be inserted into the womb to check for any abnormality. Sampling of the endometrial lining (cells in the womb) will be done with a thin tube at the same time. * take samples of womb (endometrial) lining * ask the participants questions about how they are feeling and what adverse events they are having An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
207
Intrauterine delivery system
Oral tablet
UAB Medicine Center for Research in Women's Health
Birmingham, Alabama, United States
NOT_YET_RECRUITINGWomen's Health Alliance of Mobile
Mobile, Alabama, United States
NOT_YET_RECRUITINGAMR - Mobile, AL
Mobile, Alabama, United States
NOT_YET_RECRUITINGVelocity Clinical Research - Mobile
Mobile, Alabama, United States
NOT_YET_RECRUITINGProportion of participants with Complete Resolution (CR) of NAEH
Complete Resolution will be evaluated as benign endometrium.
Time frame: At 6 months
Recurrence of NAEH after CR
Recurrence of NAEH on 3 months treatment free after CR at 6 months
Time frame: At 3 months follow up after 6 months treatment
Progression after CR
Endometrial hyperplasia with atypia or endometrial cancer after 3 months treatment free follow up after CR at 6 months
Time frame: At 3 months follow up after 6 months treatment
Proportion of participants having hysterectomy
Time frame: During treatment and 3 months follow up
Diagnosis of "benign endometrium"
Time frame: At 6 months of treatment followed by 3 month treatment-free follow up
Number of participants with adverse events
All AEs will be coded using the latest version prior to database lock of the Medical Dictionary for Regulatory Activities
Time frame: From the signing of the informed consent form (ICF) up to 3 months after the last dose of study intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
North Valley Women's Care
Glendale, Arizona, United States
NOT_YET_RECRUITINGMesa Obstetricians and Gynecologists | Research Department
Mesa, Arizona, United States
WITHDRAWNMarchand OB/GYN
Mesa, Arizona, United States
NOT_YET_RECRUITINGVelocity Clinical Research - Phoenix
Phoenix, Arizona, United States
NOT_YET_RECRUITINGCornerstone Clinic for Women - Aldersgate
Little Rock, Arkansas, United States
RECRUITINGVelvet Clinical Research
Burbank, California, United States
NOT_YET_RECRUITING...and 75 more locations